Last reviewed · How we verify
Prevention of respiratory syncytial virus (RSV) disease in adults aged 60 years and older
Approved treatments
- RSV prefusion F protein-based vaccine · Pfizer Inc.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prevention of respiratory syncytial virus (RSV) disease in adults aged 60 years and older patent landscape — cliff calendar, originator estates, attackable patents
- Prevention of respiratory syncytial virus (RSV) disease in adults aged 60 years and older treatment landscape brief
- Prevention of respiratory syncytial virus (RSV) disease in adults aged 60 years and older treatment updates RSS
Frequently asked questions about Prevention of respiratory syncytial virus (RSV) disease in adults aged 60 years and older
What drugs treat Prevention of respiratory syncytial virus (RSV) disease in adults aged 60 years and older?
Tracked treatments include RSV prefusion F protein-based vaccine.
What is the treatment for Prevention of respiratory syncytial virus (RSV) disease in adults aged 60 years and older?
Standard treatment for Prevention of respiratory syncytial virus (RSV) disease in adults aged 60 years and older includes RSV prefusion F protein-based vaccine. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prevention of respiratory syncytial virus (RSV) disease in adults aged 60 years and older patent cliff · Prevention of respiratory syncytial virus (RSV) disease in adults aged 60 years and older CI report
- Treatment: RSV prefusion F protein-based vaccine · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing